This change would bump cannabis from a Schedule I drug, sharing status with other drugs like heroin or fentanyl, to Schedule III, which is reserved for the less dangerous but still controlled substances like codeine-coated Tylenol.
Both bills give cannabis businesses access to financial services that are currently unavailable to them because of cannabis’ federal status, such as bank accounts, loans, and credit card processing capabilities
Despite growth prospects, we see massive shifts in the competitive landscape from two key sources: outside industries investing in cannabis and industry mergers and acquisitions (M&A).